False-Positive Human Immunodeficiency Virus Nucleic Acid Amplification Test After Chimeric Antigen Receptor T-Cell Therapy With Ciltacabtagene Autoleucel.
Level 4 - case-series / case-control
Case report or brief descriptive report describing diagnostic cross-reactivity.
PubMed 38288349 · doi:10.1093/ofid/ofad633
What was done
Descriptive evaluation of cross-reactivity between lentiviral vector-based chimeric antigen receptor (CAR) T-cell therapy (ciltacabtagene autoleucel) and human immunodeficiency virus (HIV) nucleic acid amplification tests (NAATs) amplifying 5' long terminal repeat and gag genes. Specific study design, patient details, and experimental methods are not specified in the abstract.
What was found
The abstract reports no numerical values, patient counts, or quantitative metrics. It reports that lentiviral vector-based CAR T-cell products cross-react with HIV NAATs targeting 5' long terminal repeat and gag genes, producing false-positive test results.
Why it matters
Clinicians need awareness that lentiviral vector-based CAR T-cell products can cause false-positive HIV NAAT results, preventing misdiagnosis and inappropriate management in oncology patients receiving ciltacabtagene autoleucel.
Limits
The abstract provides no sample size, patient demographic or clinical characteristics, specific assay performance metrics, or data on the duration of test interference.
Cited by
- supports Lentiviral vectors used to deliver genetic material in CAR-T cell therapies are engineered from modified human immunodeficiency virus (HIV).